Osteopore Ltd. · ASX:OSX
Osteopore — Investor Presentation (June 2021)
17 slides from Osteopore's investor presentation, Jun 10, 2021
Slide 1: Investor Presentation May 2021
For personal use only INVESTOR PRESENTATION MAY 2021 INVESTOR PRESENTATION OSTEOPORE.COM
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection wit h any potential investment in the Company. You should not t
Slide 3: Transformative Bone Regeneration Products
TRANSFORMATIVE BONE REGENERATION PRODUCTS For personal use only BREAKTHROUGH PROPRIETARY 3D TECHNOLOGY PRINTING TECHNOLOGY Unique implants that facilitate All Osteopore products are vascularisation to accelerate fabricated in-house using bone and tissue regeneration low cost, proprietary 3D printing
Slide 4: Investment Highlights
For personal use only REGULATORY SCALABLE INVESTMENT CLEARANCE BUSINESS MODEL HIGHLIGHTS Osteopore’s products are cleared by High margin products with low manufacturing the US FDA, Australian TGA and some capital intensity provide significant opportunity bear the CE mark of conformity to scale the b
Slide 5: Growing Revenue & Margins
GROWING REVENUE For personal use only $500 QUARTERLY SALES REVENUE IN SGD (THOUSAND) & MARGINS $422 $391 Record Q1 CY21 revenue of S$327,622 $400 21% increase in over the previous year sales $348 $348 $328 for the corresponding period $300 $271 $288 A gross margin of 68.2% of sales revenue was achie
Slide 6: Robust Cash Position to Drive Growth
For personal use only ROBUST CASH POSITION TO DRIVE GROWTH Shares on Issue A 117.2m Total Options on Issue B 13.1m ASX: OSX SHARE PRICE PAST 12 MONTHS Market Cap @ $0.475c C $55.6m $0.80 EV @ $0.475 C $47.7m $0.60 CASH BALANCE D $7.9m FY20 Average Quarterly $0.40 ($388k) Net Operating Cash Used A: S
Slide 7: Strategy That Builds Value
#3 INNOVATE Undertaking a number of early- stage, low-capital intensity For personal use only development projects with large potential upside #2 DIVERSIFY PRODUCT RANGE Osteopore is undertaking Several development #1 ACCELERATE COMMERCIAL programs to launch new REVENUE GROWTH products and expand th
Slide 8: Scalable Opportunity
SCALABLE For personal use only TOTAL NUMBER OF OPPORTUNITY SURGERY TYPE SURGERIES IN 2020 7 Craniotomy / Craniotomy closure 359,428 Burr hole for hematoma evacuation 302,570 Osteopore has superior off-the-shelf Craniectomy 89,134 products that can be manufactured at scale Burr hole for shunt placeme
Slide 9: Breakthrough Bioresorbable Products for Multiple Applications
BREAKTHROUGH BIORESORBABLE PRODUCTS FOR MULTIPLE APPLICATIONS For personal use only 1 . 1 MI LLI O N PRO CE DURE S PA Implant that is used for Implant that is used to fill the covering Burr Holes (holes void following a craniotomy in skull) after neurosurgery (the surgical removal of part of the bon
Slide 10: Improved Patient Outcomes & Lower Healthcare Costs
Osteopore implants do not require any IMPROVED PATIENT For personal use only major changes to current clinical procedures OUTCOMES & LOWER HEALTHCARE COSTS Osteopore products address an unmet clinical need by providing readily adaptable implants and reducing complication rates after surgery Provides
Slide 11: Revenue Growth Strategy: Expanding Distribution Network
REVENUE GROWTH STRATEGY EXPANDING For personal use only DISTRIBUTION Leverage distribution partnerships in the key markets to accelerate revenue growth NETWORK DISTRIBUTION 23 PARTNERS CURRENTLY TARGETING Ensure sales teams and surgeons are educated and supported to drive adoption and sales ~1.1 mil
Slide 12: Foundational Markets
For personal use only AUSTRALIA ASIA FOUNDATIONAL Well established and experienced & NZ Hired dedicated Business MARKETS distribution partner network in South Korea, Vietnam, Singapore and Australia Development person in Sydney Australia 2020 constant currency year-on-year Signed Australian & NZ rev
Slide 13: Priority Market Expansion
PRIORITY MARKET EXPANSION For personal use only Recently received CE Mark for expanded product variants and shelf life Europe USA CHINA JAPAN + UK Signed US Distribution Signed Co-operation Identify and engage KOL Signed German-Austrian Agreement with Bioplate agreement with Boao Yiling surgeons int
Slide 14: Future Commercial Opportunities
REGENERATION OF OTHER TISSUE VETERINARY MARKETS For personal use only Osteopore has successfully completed Osteopore has successfully completed multiple animal trials for knee cartilage animal trials for a number of different surgical regeneration, and the Osteopore scaffold applications which could
Slide 15: 2021 Commercial Priorities
2021 COMMERCIAL PRIORITIES For personal use only ACCELERATE REVENUE GROWTH DIVERSIFICATION INNOVATION Experiment with promising novel compound Leverage cranial and maxillofacial products with Leverage dental product regulatory combinations, including PCL-TCP and PCL-TCP- regulatory approval in signi
Slide 16: Sources
SOURCES For personal use only 1 Dimitriou, R., Mataliotakis, G. I., Angoules, A. G., Kanakaris, N. K., & Giannoudis, P. V. (2011). Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. Injury, 42, S3-S15. 2 Younger, E. M., & Chapman, M.
Slide 17: For personal use only
For personal use only Carl Runde Chief Financial Officer M +61 400 118 017 E: carl_runde@osteopore.com INVESTOR PRESENTATION OSTEOPORE.COM 17